

Product Specification Sheet

Product Name: SYN115

Catalog Number: C7911

Technical information:

Chemical Formula: C₁₉H₂₆N₄O₄S

CAS #: 870070-55-6

Molecular Weight: 406.5

Purity: > 98%

Appearance: White solid

Solubility: Soluble in DMSO up to 50 mM

Chemical Name: 4-Hydroxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-methyl-1-piperidinecarboxamide

Storage: Store solid powder at 4°C desiccated; Store DMSO solution at -20°C.

Shelf Life: In the unopened package, powder is stable for 1 year and DMSO solution is stable for 6 months

under proper storage condition.

Handling: • To make 10 mM stock solution, add 0.246mL of DMSO for each mg of SYN115.

• For DMSO solution, briefly spin the vial at 500 rpm in a 50 mL conical tube to ensure maximum

SYN115

sample recovery.

Biological Activity: SYN115 (Tozadenant) is a orally-available, benzothiazole-based, antagonist of the Adenosine A2A

receptor for the treatment of Parkinson's disease and other CNS-related conditions. SYN115 is being pursued as a monotherapy as well as in combination with L-dopamine and is being studied

for its potential neuroprotective effects. [1]

Animal studies with SYN115 support beliefs that A2A antagonists reduce Parkinson's symptoms by reducing the inhibitory output of the basal ganglia indirect pathway. Using Cerebral Blood Flow

(CBF) as a pharmacodynamic parameter, studies have shown that SYN115 induces a significant decrease in thalamic CBF, consistent with the deactivation of the indirect pathway. [2]

Reference: 1. Biotie Therapies website (2013-04-24)

2. Black et al., Quantification of Indirect Pathway Inhibition by the Adenosine A2a Antagonist SYN115 in Parkinson Disease. Black et al., J. Neurosci. 2010, 30(48), 16284-16292. Pubmed ID: 21123574

To reorder: http://www.cellagentech.com/SYN115/

For Technical Support: <u>technical@cellagentech.com</u>

Chemicals are sold for research use only, not for clinical or diagnostic use.